Ultrasound Guided Psoas Compartment Block vs Suprainguinal Fascia Iliaca Compartment Block

NCT ID: NCT05543109

Last Updated: 2022-09-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

85 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-29

Study Completion Date

2023-02-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to compare the intraoperative and the postoperative analgesic effect of psoas compartment block (PCB) and supra-inguinal fascia iliaca compartment block (SFIB) in pediatric patients undergoing developmental dysplasia of the hip

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All subjects after entering operation room will be connected to standard monitor electrocardiograph, non-invasive blood pressure, heart rate, oxygen saturation.

Three mg/kg of propofol, 0.2 μg/kg of fentanyl and 0.1 mg/kg midazolam will be used for sedation. Oxygen at the concentration of 100% will be administrated under the mask in all patients after satisfactory sedation, tracheal intubation will be performed after intravenous anesthesia with administration of 3 mg/kg of propofol, 0.6 μg/kg of fentanyl and 0.9 mg/kg of rocurium. After intubation 2-3% of sevoflurane and 0.2-0.3 mcg/kg/min of fentanyl will be used to maintain anesthesia guided by PSI and hemodynamic monitoring.

The two groups will receive nerve block with local anesthetics. In the SFIB group, the patients will receive ultrasound-guided SFIB, while the patients in the PCB group will receive PCB under the guidance of ultrasound.

Local anesthetic 0.25% Ropivacaine will be used at 1 ml/kg for SFIB and PCB. (the dose of local anesthetic for SFIB or PCB was not more than 35ml). All blocks will be performed by the same experienced anesthesiologist.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Postoperative Hip Dysplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Psoas compartment block

After induction of anesthesia; ultrasound guided psoas compartment block will be done using ropivacaine 0.25% 1ml/kg.

Group Type ACTIVE_COMPARATOR

Fentanyl

Intervention Type DRUG

1 mic/kg during induction of anesthesia

Propofol

Intervention Type DRUG

3mg/kg during induction of anesthesia

Rocuronium

Intervention Type DRUG

0.9 mg/kg during induction of anesthesia

Sevoflurane

Intervention Type DRUG

2-3% during maintanance of anesthesia

Ropivacaine

Intervention Type DRUG

0.25% Ropivacaine will be used at 1 ml/kg will be injected Ultrasound guided after induction of general anesthesia.

Suprainguinal fascia iliaca compartment block

After induction of anesthesia; ultrasound guided suprainguinal fascia iliaca compartment block will be done using ropivacaine 0.25% 1ml/kg.

Group Type ACTIVE_COMPARATOR

Fentanyl

Intervention Type DRUG

1 mic/kg during induction of anesthesia

Propofol

Intervention Type DRUG

3mg/kg during induction of anesthesia

Rocuronium

Intervention Type DRUG

0.9 mg/kg during induction of anesthesia

Sevoflurane

Intervention Type DRUG

2-3% during maintanance of anesthesia

Ropivacaine

Intervention Type DRUG

0.25% Ropivacaine will be used at 1 ml/kg will be injected Ultrasound guided after induction of general anesthesia.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fentanyl

1 mic/kg during induction of anesthesia

Intervention Type DRUG

Propofol

3mg/kg during induction of anesthesia

Intervention Type DRUG

Rocuronium

0.9 mg/kg during induction of anesthesia

Intervention Type DRUG

Sevoflurane

2-3% during maintanance of anesthesia

Intervention Type DRUG

Ropivacaine

0.25% Ropivacaine will be used at 1 ml/kg will be injected Ultrasound guided after induction of general anesthesia.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Narcotic Intravenous anesthetic Muscle relaxant Inhalational anesthetic Local anesthetic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing undergo acetabuloplasty
* Anesthesiologists (ASA) physical status of I to II

Exclusion Criteria

* Known allergy to local anesthetic
* Infection at the block site.
Minimum Eligible Age

1 Year

Maximum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tanta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mona Mohamed Mogahed

Associate professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mona Mohamed Mogahed

Tanta, Elgharbia, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

35635/8/22

Identifier Type: -

Identifier Source: org_study_id